The treatment options of diabetes have been divided into insulin therapies (insulin and its analogs) and non-insulin therapies such as insulin sensitizers (Biguanides, Thiazolidinediones), secretagogues (Sulfonylureas, Glinides), alpha-glucosidase inhibitors, incretins (such as DPP-4 inhibitors and GLP-1 receptor agonists), Pramlintide, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (4, 5). This evidence concerns the gene SLC5A2 and diabetes mellitus.